A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

被引：0
|
作者：
Gericke, Germo [1 ]
机构：
[1] Novartis Co, Adv Accelerator Applicat, CH-1204 Geneva, Switzerland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / 09期
关键词：
1;
D O I：
10.1007/s00259-021-05400-5
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：2666 / 2667
页数：2
相关论文
共 50 条
  • [31] Development and preclinical evaluation of novel 177Lu-labelled radiohybrid CCK-2R-targeted ligands based on [177Lu]Lu-DOTA-PP-F11N
    Holzleitner, N.
    Guenther, T.
    Lapa, C.
    Wester, H. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S143 - S144
  • [32] Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
    Sue Ping Thang
    Violet, John
    Sandhu, Shahneen
    Iravani, Amir
    Akhurst, Tim
    Kong, Grace
    Kumar, Aravind Ravi
    Murphy, Declan G.
    Williams, Scott G.
    Hicks, Rodney J.
    Hofman, Michael S.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 670 - 676
  • [33] Peptide Receptor Radionuclide Therapy of Non-radioiodine AvidorRadioiodine Therapy RefractoryDifferentiated Thyroid Cancer and Medullary Thyroid Cancer using 90Y- and 177Lu-labelled Somatostatin Analogs
    Liu, Qingxing
    Zhang, Jingjing
    Singh, Aviral
    Schuchardt, Christiane
    Kulkarni, Harshad
    Zhu, Zhaohui
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [34] Ambient Dose Equivalent and Occupational Exposure for 177Lu-PSMA-I&T Radionuclide Therapy
    Hu, Z.
    Liu, C.
    Liu, J.
    Yang, Z.
    Qiu, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S735 - S735
  • [35] Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Ling, Sui Wai
    de Blois, Erik
    Hooijman, Eline
    van der Veldt, Astrid
    Brabander, Tessa
    PHARMACEUTICS, 2022, 14 (10)
  • [36] Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1002 - 1003
  • [37] Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy
    Zha, Zhihao
    Ploessl, Karl
    Choi, Seok Rye
    Zhao, Ruiyue
    Jin, Wenbin
    Wang, Ran
    Alexoff, David
    Zhu, Lin
    Kung, Hank F.
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (17) : 12602 - 12613
  • [38] SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
    Hope, Thomas A.
    Antonarakis, Emmanuel S.
    Bodei, Lisa
    Calais, Jeremie
    Iravani, Amir
    Jacene, Heather
    Koo, Phillip J.
    Morgans, Alicia K.
    Osborne, Joseph R.
    Tagawa, Scott T.
    Taplin, Mary-Ellen
    Sartor, Oliver
    Morris, Michael J.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (09) : 1417 - 1423
  • [39] Single-Time-Point Dosimetry of 177Lu-PSMA-617 Radionuclide Therapy with SPECT/CT
    Burkerr, Brian J.
    RADIOLOGY-IMAGING CANCER, 2023, 5 (02):
  • [40] Concomitant Dosimetry during 177-lu labelled Radionuclide therapy in comparison with conventional Dosimetry using 111-in labelled peptides
    Heute, D.
    Dobrozemsky, G.
    Warwitz, B.
    Gabriel, M.
    von Guggenberg, E.
    Virgolini, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S180 - S180
12345